Neurologists Karissa Gable, MD, FAAN, and Jeffrey Allen, MD, discuss how treatment success in CIDP extends beyond disease stabilization, emphasizing meaningful functional improvement and patient-centered goals.
Impact of Efgartigimod on INCAT Scores in CIDP: ADHERE/ADHERE+ Post Hoc Analysis
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Roche Unveils PrevenTRON, a Phase 3 Prevention Trial of Trontinemab in Cognitively Unimpaired Individuals at High Risk of Alzheimer Decline
2
Alzheimer's Association Launches PROTECT-Cog Combination Prevention Trial
3
Sanofi's Oral TREM2 Agonist SAR448851 Advances to Phase 2 TREMHANCE Trial in Early Alzheimer Disease
4
The Hidden Cost of the Beautiful Game: Part 1
5